However, PTX3 also has the inhibitory effect on angiogenesis and is able to moderate malignant progression in bladder cancer (52), multiple myeloma (62), fibrosarcoma (63), and prostate cancer (64). Here, PTX3 is linked to plasma cell myeloma.